SEC Form 4 · accession 0001209191-15-013666
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Perry A Karsen
Officer — see remarks
Period of report
Feb 11, 2015
Accepted (ET)
Feb 13, 2015 · 5:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 11, 2015 | M | 8,324 | $34.70 | A | 78,441 | D | |
| Common Stock | Feb 11, 2015 | M | 8,324 | $36.675 | A | 86,765 | D | |
| Common Stock | Feb 11, 2015 | M | 11,248 | $40.22 | A | 98,013 | D | |
| Common StockF1 | Feb 11, 2015 | S | 27,896 | $120.115 | D | 70,117 | D | |
| Common Stock | holding | — | — | — | 2,000 | I | IRA Account | |
| Common Stock | holding | — | — | — | 1,638 | I | 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F2 | $34.70 | Feb 11, 2015 | M | 8,324 | D | — | Jul 30, 2022 | Common Stock | 8,324 | 4,162 | D |
| Stock Option (right to buy)F3,F2 | $36.675 | Feb 11, 2015 | M | 8,324 | D | — | Oct 31, 2022 | Common Stock | 8,324 | 4,162 | D |
| Stock Option (right to buy)F3,F2 | $40.22 | Feb 11, 2015 | M | 11,248 | D | — | Dec 17, 2022 | Common Stock | 11,248 | 5,626 | D |
Explanation of responses
- F1The price report in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan in multiple transactions at prices ranging from $119.71 to $120.67, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The option was fully exercisable.
- F3The option was issued pursuant to the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013).
Remarks
Chief Executive Officer, Celgene Cellular Therapuetics